These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31713782)

  • 1. Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis.
    Golan M; Mausner-Fainberg K; Ibrahim B; Benhamou M; Wilf-Yarkoni A; Kolb H; Regev K; Karni A
    CNS Drugs; 2019 Dec; 33(12):1229-1237. PubMed ID: 31713782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire.
    Blumenfeld-Kan S; Staun-Ram E; Miller A
    Mult Scler Relat Disord; 2019 Sep; 34():29-37. PubMed ID: 31228713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
    Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
    J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    Smith PA; Schmid C; Zurbruegg S; Jivkov M; Doelemeyer A; Theil D; Dubost V; Beckmann N
    J Neuroimmunol; 2018 May; 318():103-113. PubMed ID: 29530550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables.
    Pitteri M; Magliozzi R; Bajrami A; Camera V; Calabrese M
    Expert Opin Pharmacother; 2018 Mar; 19(4):387-395. PubMed ID: 29397790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis.
    Bascuñana P; Möhle L; Brackhan M; Pahnke J
    Drugs R D; 2020 Sep; 20(3):197-207. PubMed ID: 32696271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod anti-inflammatory and neuroprotective effects modulation of RAGE axis in multiple sclerosis patients.
    Sternberg Z; Kolb C; Chadha K; Nir A; Nir R; George R; Johnson J; Yu J; Hojnacki D
    Neuropharmacology; 2018 Mar; 130():71-76. PubMed ID: 29197515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis.
    Linker RA; Lee DH; Demir S; Wiese S; Kruse N; Siglienti I; Gerhardt E; Neumann H; Sendtner M; Lühder F; Gold R
    Brain; 2010 Aug; 133(Pt 8):2248-63. PubMed ID: 20826430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
    J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remyelination modulators in multiple sclerosis patients.
    Al-Temaimi R; AbuBaker J; Al-Khairi I; Alroughani R
    Exp Mol Pathol; 2017 Dec; 103(3):237-241. PubMed ID: 29108879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod.
    Montarolo F; Perga S; Martire S; Brescia F; Caldano M; Lo Re M; Panzica G; Bertolotto A
    Eur J Neurol; 2019 Apr; 26(4):667-672. PubMed ID: 30565812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination.
    Linker R; Gold R; Luhder F
    Crit Rev Immunol; 2009; 29(1):43-68. PubMed ID: 19348610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.
    Luessi F; Kraus S; Trinschek B; Lerch S; Ploen R; Paterka M; Roberg T; Poisa-Beiro L; Klotz L; Wiendl H; Bopp T; Jonuleit H; Jolivel V; Zipp F; Witsch E
    Mult Scler; 2015 Dec; 21(14):1811-22. PubMed ID: 25732840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
    Aharoni R; Kayhan B; Eilam R; Sela M; Arnon R
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14157-62. PubMed ID: 14614135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.
    Zinger A; Latham SL; Combes V; Byrne S; Barnett MH; Hawke S; Grau GE
    Mult Scler; 2016 Dec; 22(14):1883-1887. PubMed ID: 26931477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis.
    Mirowska-Guzel D
    Immunopharmacol Immunotoxicol; 2009; 31(1):32-8. PubMed ID: 18792835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.
    Hohlfeld R; Kerschensteiner M; Stadelmann C; Lassmann H; Wekerle H
    J Neuroimmunol; 2000 Jul; 107(2):161-6. PubMed ID: 10854651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.